Development and validation of a risk model with variables related to non-small cell lung cancer in patients with pulmonary nodules: a retrospective study

被引:0
|
作者
Liao, Zufang [1 ]
Zheng, Rongjiong [2 ]
Li, Ni [3 ]
Shao, Guofeng [3 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Ningbo 315041, Zhejiang, Peoples R China
[2] Ningbo Yinzhou 2 Hosp, Ningbo 315192, Zhejiang, Peoples R China
[3] Ningbo Univ, Dept Cardiothorac Surg, Li Huili Hosp, Xingning Rd 57, Ningbo 315041, Zhejiang, Peoples R China
关键词
NSCLC; Pulmonary nodules; Logistic; Variables; Model; GROUND-GLASS OPACITY; SOCIETY GUIDELINES; PROBABILITY; MANAGEMENT; BLOCKERS; TISSUE;
D O I
10.1186/s12885-023-11385-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLung cancer is a major global threat to public health for which a novel predictive nomogram is urgently needed. Non-small cell lung cancer (NSCLC) which accounts for the main port of lung cancer cases is attracting more and more people's attention.Patients and methodsHere, we designed a novel predictive nomogram using a design dataset consisting of 515 pulmonary nodules, with external validation being performed using a separate dataset consisting of 140 nodules and a separate dataset consisting of 237 nodules. The selection of significant variables for inclusion in this model was achieved using a least absolute shrinkage and selection operator (LASSO) logistic regression model, after which a corresponding nomogram was developed. C-index values, calibration plots, and decision curve analyses were used to gauge the discrimination, calibration, and clinical utility, respectively, of this predictive model. Validation was then performed with the internal bootstrapping validation and external cohorts.ResultsA predictive nomogram was successfully constructed incorporating hypertension status, plasma fibrinogen levels, blood urea nitrogen (BUN), density, ground-glass opacity (GGO), and pulmonary nodule size as significant variables associated with nodule status. This model exhibited good discriminative ability, with a C-index value of 0.765 (95% CI: 0.722-0.808), and was well-calibrated. In validation analyses, this model yielded C-index values of 0.892 (95% CI: 0.844-0.940) for external cohort and 0.853 (95% CI: 0.807-0.899) for external cohort 2. In the internal bootstrapping validation, C-index value could still reach 0.753. Decision curve analyses supported the clinical value of this predictive nomogram when used at a NSCLC possibility threshold of 18%.ConclusionThe nomogram constructed in this study, which incorporates hypertension status, plasma fibrinogen levels, BUN, density, GGO status, and pulmonary nodule size, was able to reliably predict NSCLC risk in this Chinese cohort of patients presenting with pulmonary nodules.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients A multicenter retrospective study
    Roh, Jiyeon
    Ahn, Hyo Yeong
    Kim, Insu
    Son, Ju Hyeong
    Seol, Hee Yun
    Kim, Mi Hyun
    Lee, Min Ki
    Eom, Jung Seop
    MEDICINE, 2021, 100 (19) : E25748
  • [42] Potential Implications of the Lung Microbiota in Patients with Chronic Obstruction Pulmonary Disease and Non-Small Cell Lung Cancer
    He, Jia-Qi
    Chen, Qin
    Wu, Sheng-Jun
    Wang, De-Qin
    Zhang, Shen-Yingjie
    Zhang, Song-Zhao
    Chen, Rui-Lin
    Wang, Jia-Feng
    Wang, Zhen
    Yu, Chen-Huan
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [43] Development and Validation of a Clinical Prediction Model for N2 Lymph Node Metastasis in Non-Small Cell Lung Cancer
    Chen, Kezhong
    Yang, Fang
    Jiang, Guanchao
    Li, Jianfeng
    Wang, Jun
    ANNALS OF THORACIC SURGERY, 2013, 96 (05): : 1761 - 1768
  • [44] Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules—a literature review
    Sara E. Dahlsgaard-Wallenius
    Malene Grubbe Hildebrandt
    Allan Johansen
    Mie Holm Vilstrup
    Henrik Petersen
    Oke Gerke
    Poul Flemming Høilund-Carlsen
    Anni Morsing
    Thomas Lund Andersen
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 584 - 591
  • [45] Are patients with chronic obstructive pulmonary disease at a greater risk for the development of autoimmune thyroiditis as an adverse event of immunotherapy in non-small cell lung cancer treatment?
    Zecevic, Andrej
    Blanka-Protic, Ana
    Jandric, Aleksandar
    Adzic-Vukicevic, Tatjana
    PATHOLOGY & ONCOLOGY RESEARCH, 2025, 31
  • [46] VALIDATION OF GENE EXPRESSION BIOMARKER PANELS IN NON-SMALL CELL LUNG CANCER
    Dong, Jie
    Huebner, Marianne
    Azodo, Ijeoma
    Tomaszek, Sandra C.
    Sun, Zhifu
    Kosari, Farhad
    Wang, Lifeng
    Jen, Jin
    Aubry, Marie Christine
    Yang, Ping
    Vasmatzis, George
    Wigle, Dennis A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S279 - S279
  • [47] Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer
    Bowman, Isaac A.
    Pedrosa, Ivan
    Kapur, Payal
    Brugarolas, James
    CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : E675 - E680
  • [48] A population-based study of gefitinib in patients with non-small cell lung cancer
    Hayashibara, Kenji
    Satoh, Hiroaki
    Shinohara, Yoko
    Inagaki, Masaharu
    Kaburagi, Takayuki
    Hashimoto, Toshio
    Kurishima, Koichi
    Ishikawa, Hiroichi
    Ichimura, Hideo
    Nawa, Takeshi
    Funayama, Yasunori
    Matsumura, Takeshi
    Kagohashi, Katsunori
    Endo, Takeshi
    Furukawa, Kinya
    Kishi, Koji
    Sumi, Masaaki
    Kamiyama, Koichi
    Ishikawa, Shigemi
    MEDICAL ONCOLOGY, 2009, 26 (02) : 222 - 227
  • [49] Efficacy of Osimertinib in Patients of Advanced Non-Small Cell Lung Cancer with Brain Metastasis: A Retrospective Analysis
    Zhang, J.
    Chen, L.
    Ye, M.
    Li, H.
    Zhou, C.
    Pan, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S911 - S912
  • [50] The development of potential targets in the treatment of non-small cell lung cancer
    Zhang, Jimin
    Lin, Zhihui
    OPEN LIFE SCIENCES, 2016, 11 (01): : 225 - 231